Navigation Links
Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Date:3/25/2008

ch actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at http://www.sec.gov and the Canadian securities regulatory authorities at http://www.sedar.com.

Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.


'/>"/>
SOURCE Astellas Pharma US, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
5. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
6. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
9. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
10. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
11. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Novartis, ranibizumab was approved by CFDA ... 2012. Currently, only Lucentis, a product of Novartis, is ... as the first self- developed drug for the treatment ...
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015 /PRNewswire/ ... that its shareholders have approved Mylan,s proposed acquisition ... TASE) and the related issuance of Mylan ordinary ... meeting of shareholders held today. The transaction received ... extraordinary general meeting. In addition, the transaction received ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics ... to go deep sea diving. The act of recreational diving exposes the ... these reasons, it is vital that all recreational and professional divers undergo regular ...
(Date:8/28/2015)... (PRWEB) , ... August 28, ... ... Services, Inc.’s (AIS) Medicare-Medicaid Dual Eligibles Database have added comprehensive information on ... alignment demonstration approved for a December 2015 launch; and Idaho’s partnership to ...
(Date:8/28/2015)... AB (PRWEB) , ... August 28, 2015 , ... External ... The Heart Fit Clinic is now selling External Counterpulsation (EECP or ECP) machines with ... Heart Fit Clinic has been in business since 2007 helping people prevent and ...
(Date:8/28/2015)... ... 2015 , ... A complimentary webinar offered by healthcare consulting and accounting firm ... proposal to mandate bundled payments through the Comprehensive Care for Joint Replacement Program ... Care for Joint Replacement,” takes place at 12 noon EDT on Wednesday, September 2, ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... Inc. ’s online medical consultations result in high percentages of change to treatment ... the Center for Healthcare Informatics at Tennessee Tech University and analyzed WorldCare’s second ...
Breaking Medicine News(10 mins):Health News:Healthpointe Now Offering Scuba Physicals 2Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:PYA Offers Complimentary CCJR Webina — Game On 2Health News:PYA Offers Complimentary CCJR Webina — Game On 3Health News:WorldCare International, Inc. Celebrates Findings of Independent ROI Study 2
... Scientists presented new research today demonstrating the impact ... studies examine how such environmental information can be transmitted ... known as epigenetics. This new knowledge could ultimately improve ... and how a parent,s exposure to drugs, alcohol, and ...
... common among cardiac arrest survivors. The survival and ... patients with preexisting cardiomyopathy, compared with those patients ... presented Nov. 14 at the at the American ... Therefore, the researchers recommended the use of therapeutic ...
... research linking alcohol to breast cancer risk, a new study ... that adolescent girls with a family history of breast disease ... cancer have a higher risk of developing benign breast ... without a family history, this already-elevated risk rises with increasing ...
... non-small cell lung cancer who have mutations in the KRAS ... according to results of a recent study conducted by Quintiles ... "Our findings indicate that when patients with lung cancer have ... to antifolate drugs," said lead researcher Sarah Bacus, Ph.D., Quintiles ...
... team of researchers co-led by the University of Pennsylvania ... capable of recording brain activity from the cortical surface ... make possible a whole new generation of brain-computer interfaces ... work was published in Nature Neuroscience. ...
... in people with dangerous heart arrhythmias, according to research ... , Wearable cardioverter defibrillators are used by people who ... including those with weakened heart function, awaiting cardiac transplant ... from receiving an implanted defibrillator. , The device ...
Cached Medicine News:Health News:Nature and nurture work together to shape the brain 2Health News:Hypothermia remains effective in cardiac arrest patients with preexisting cardiomyopathy 2Health News:Girls with family history of breast disease should avoid alcohol 2Health News:Girls with family history of breast disease should avoid alcohol 3Health News:Antifolates show promise against NSCLC subtype 2Health News:A more flexible window into the brain 2Health News:A more flexible window into the brain 3Health News:Wearable defibrillator can prevent death in people with arrhythmias 2
1000 L, Racked, Pre-sterilized, 100 tips/rack Recommended for 500 and 1000 L pipettes....
Inquire...
300 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 250 and 300 L pipettes....
... false signals and contamination caused by ... Barrier Tips offer performance and economy ... (PCR(a)), radioactive isotopes, tissue culture fluids, ... , ,Promega Barrier Tips are made ...
Medicine Products: